ArticleBMC musculoskeletal disorders2026
Clinical and treatment-related determinants of advanced-stage femoral head osteonecrosis following COVID-19: a five-year retrospective cohort study.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to evaluate clinical and treatment-related factors associated with advanced-stage femoral head avascular necrosis (AVN) (Ficat stage III-IV) in patients who developed osteonecrosis following COVID-19 infection, based on long-term follow-up data.
methodsThis single-center retrospective cohort study included patients diagnosed with femoral head AVN after confirmed COVID-19 infection who had at least five years of clinical and radiological follow-up. Demographic characteristics, comorbidities, clinical severity of COVID-19, duration of hospitalization, intensive care unit (ICU) requirement, type and duration of systemic corticosteroid therapy, and duration of antiviral treatment were recorded. AVN was staged according to the Ficat and Arlet classification. Patients were divided into early-stage (stage I-II) and advanced-stage (stage III-IV) groups. Independent predictors of advanced-stage AVN were evaluated using logistic regression analysis. Receiver operating characteristic (ROC) analysis was performed to determine the discriminatory ability of antiviral treatment duration for advanced-stage disease. Time to osteonecrosis was defined as the interval between confirmed RT-PCR diagnosis of COVID-19 and first MRI confirmation of femoral head AVN.
resultsA total of 40 patients were included. Advanced-stage AVN was significantly associated with longer hospitalization duration, prolonged corticosteroid use, extended antiviral treatment, and the presence of hypertension. Multivariable logistic regression analysis identified hypertension, hospitalization duration, steroid treatment duration, and antiviral treatment duration as independent risk factors for advanced-stage AVN. ROC analysis demonstrated that an antiviral treatment duration ≥ 9.5 days showed excellent discriminatory performance for advanced-stage AVN (AUC = 0.950). These results reflect associations within a selected cohort of patients with post-COVID AVN and do not imply a direct causal relationship. However, this finding should be interpreted with caution due to the limited sample size and should be considered exploratory rather than definitive.
conclusionsIn patients who develop femoral head AVN following COVID-19 infection, disease progression appears closely related to the clinical severity of COVID-19 and overall treatment burden. Patients with severe COVID-19 requiring prolonged hospitalization and extended treatment exposure should be carefully monitored for progression to advanced-stage AVN. The identified cut-off value should be considered hypothesis-generating rather than definitive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.